Quels facteurs de risque sont étudiés avec les A549 ?
Des facteurs comme le tabagisme, l'exposition à des agents chimiques et la pollution.
Facteurs de risquePollution
#2
Les A549 aident-elles à identifier des facteurs génétiques ?
Elles peuvent être utilisées pour étudier l'expression génique liée à des prédispositions au cancer.
Facteurs génétiquesExpression génique
#3
Comment les A549 sont-elles utilisées pour étudier l'environnement ?
Elles permettent d'évaluer l'impact des toxines environnementales sur les cellules pulmonaires.
Toxines environnementalesImpact environnemental
#4
Peut-on étudier l'alimentation avec les A549 ?
Indirectement, elles peuvent être utilisées pour explorer l'impact des nutriments sur le cancer.
AlimentationNutriments
#5
Les A549 sont-elles utiles pour étudier le stress oxydatif ?
Oui, elles sont souvent utilisées pour examiner les effets du stress oxydatif sur les cellules.
Stress oxydatifCellules
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cellules A549 : Questions médicales les plus fréquentes",
"headline": "Cellules A549 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cellules A549 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-28",
"dateModified": "2025-03-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cellules A549"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cellules épithéliales",
"url": "https://questionsmedicales.fr/mesh/D004847",
"about": {
"@type": "MedicalCondition",
"name": "Cellules épithéliales",
"code": {
"@type": "MedicalCode",
"code": "D004847",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.436"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cellules A549",
"alternateName": "A549 Cells",
"code": {
"@type": "MedicalCode",
"code": "D000072283",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Wenfei Zhao",
"url": "https://questionsmedicales.fr/author/Wenfei%20Zhao",
"affiliation": {
"@type": "Organization",
"name": "Department of Respiratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China."
}
},
{
"@type": "Person",
"name": "Hongyun Li",
"url": "https://questionsmedicales.fr/author/Hongyun%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Respiratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China."
}
},
{
"@type": "Person",
"name": "Shanshan Yang",
"url": "https://questionsmedicales.fr/author/Shanshan%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Respiratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China."
}
},
{
"@type": "Person",
"name": "Di Guo",
"url": "https://questionsmedicales.fr/author/Di%20Guo",
"affiliation": {
"@type": "Organization",
"name": "Department of Respiratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China."
}
},
{
"@type": "Person",
"name": "Jing Chen",
"url": "https://questionsmedicales.fr/author/Jing%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Department of Respiratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Pinnae and facial hypertrichosis induced by cetuximab.",
"datePublished": "2022-07-12",
"url": "https://questionsmedicales.fr/article/35821579",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10781552221114073"
}
},
{
"@type": "ScholarlyArticle",
"name": "An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer.",
"datePublished": "2022-06-07",
"url": "https://questionsmedicales.fr/article/35696702",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/COC.0000000000000926"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells.",
"datePublished": "2023-01-09",
"url": "https://questionsmedicales.fr/article/36668877",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/toxins15010057"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer.",
"datePublished": "2023-01-19",
"url": "https://questionsmedicales.fr/article/36656444",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s43046-023-00160-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated",
"datePublished": "2022-12-21",
"url": "https://questionsmedicales.fr/article/36546659",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1056/NEJMoa2212419"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Cellules épithéliales",
"item": "https://questionsmedicales.fr/mesh/D004847"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cellules A549",
"item": "https://questionsmedicales.fr/mesh/D000072283"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cellules A549 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cellules A549",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cellules A549",
"description": "Comment identifier les cellules A549 en laboratoire ?\nQuelles techniques sont utilisées pour étudier les cellules A549 ?\nLes cellules A549 sont-elles tumorales ?\nPeut-on détecter des marqueurs spécifiques dans les A549 ?\nLes cellules A549 sont-elles sensibles à des médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D000072283?mesh_terms=Cetuximab#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cellules A549",
"description": "Quels symptômes sont associés aux cellules A549 ?\nLes cellules A549 peuvent-elles simuler des symptômes humains ?\nComment les A549 aident-elles à comprendre les symptômes du cancer ?\nLes cellules A549 montrent-elles des signes de stress cellulaire ?\nPeut-on observer des symptômes de résistance dans les A549 ?",
"url": "https://questionsmedicales.fr/mesh/D000072283?mesh_terms=Cetuximab#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cellules A549",
"description": "Les cellules A549 aident-elles à la prévention du cancer ?\nComment les A549 contribuent-elles à la recherche préventive ?\nPeut-on utiliser les A549 pour étudier des facteurs de risque ?\nLes A549 sont-elles utiles pour la recherche sur le tabagisme ?\nComment les A549 aident-elles à comprendre la prévention des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D000072283?mesh_terms=Cetuximab#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cellules A549",
"description": "Quels traitements sont testés sur les cellules A549 ?\nLes A549 sont-elles utilisées pour des essais cliniques ?\nComment les A549 aident-elles à développer de nouveaux traitements ?\nLes cellules A549 peuvent-elles prédire la réponse au traitement ?\nQuels agents sont souvent testés sur les A549 ?",
"url": "https://questionsmedicales.fr/mesh/D000072283?mesh_terms=Cetuximab#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cellules A549",
"description": "Quelles complications peuvent être étudiées avec les A549 ?\nLes A549 peuvent-elles simuler des complications pulmonaires ?\nComment les A549 aident-elles à comprendre les complications du cancer ?\nPeut-on étudier la résistance aux traitements avec les A549 ?\nLes A549 sont-elles impliquées dans des complications métaboliques ?",
"url": "https://questionsmedicales.fr/mesh/D000072283?mesh_terms=Cetuximab#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cellules A549",
"description": "Quels facteurs de risque sont étudiés avec les A549 ?\nLes A549 aident-elles à identifier des facteurs génétiques ?\nComment les A549 sont-elles utilisées pour étudier l'environnement ?\nPeut-on étudier l'alimentation avec les A549 ?\nLes A549 sont-elles utiles pour étudier le stress oxydatif ?",
"url": "https://questionsmedicales.fr/mesh/D000072283?mesh_terms=Cetuximab#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les cellules A549 en laboratoire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules A549 peuvent être identifiées par leur morphologie et leur croissance en culture."
}
},
{
"@type": "Question",
"name": "Quelles techniques sont utilisées pour étudier les cellules A549 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les techniques incluent la microscopie, la cytométrie en flux et les tests de viabilité cellulaire."
}
},
{
"@type": "Question",
"name": "Les cellules A549 sont-elles tumorales ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les cellules A549 proviennent d'un adénocarcinome, ce qui les rend tumorales."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des marqueurs spécifiques dans les A549 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des marqueurs comme le CD44 et le p53 peuvent être analysés dans les A549."
}
},
{
"@type": "Question",
"name": "Les cellules A549 sont-elles sensibles à des médicaments ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent utilisées pour tester la sensibilité aux chimiothérapies."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés aux cellules A549 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules A549 ne présentent pas de symptômes, car elles sont in vitro."
}
},
{
"@type": "Question",
"name": "Les cellules A549 peuvent-elles simuler des symptômes humains ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être utilisées pour étudier des symptômes liés aux maladies pulmonaires."
}
},
{
"@type": "Question",
"name": "Comment les A549 aident-elles à comprendre les symptômes du cancer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'étudier la réponse des cellules tumorales aux traitements et aux facteurs de croissance."
}
},
{
"@type": "Question",
"name": "Les cellules A549 montrent-elles des signes de stress cellulaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent montrer des signes de stress en réponse à des agents cytotoxiques."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes de résistance dans les A549 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être utilisées pour étudier la résistance aux médicaments anticancéreux."
}
},
{
"@type": "Question",
"name": "Les cellules A549 aident-elles à la prévention du cancer ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, elles sont utilisées pour étudier les mécanismes de la carcinogenèse."
}
},
{
"@type": "Question",
"name": "Comment les A549 contribuent-elles à la recherche préventive ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'identifier des biomarqueurs et des cibles pour la prévention du cancer."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser les A549 pour étudier des facteurs de risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont utilisées pour étudier l'impact de divers facteurs environnementaux sur le cancer."
}
},
{
"@type": "Question",
"name": "Les A549 sont-elles utiles pour la recherche sur le tabagisme ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent utilisées pour étudier les effets du tabagisme sur les cellules pulmonaires."
}
},
{
"@type": "Question",
"name": "Comment les A549 aident-elles à comprendre la prévention des maladies ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'explorer les mécanismes de protection et les interventions préventives."
}
},
{
"@type": "Question",
"name": "Quels traitements sont testés sur les cellules A549 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements anticancéreux et les thérapies ciblées sont souvent testés sur ces cellules."
}
},
{
"@type": "Question",
"name": "Les A549 sont-elles utilisées pour des essais cliniques ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles sont utilisées pour des études précliniques et non pour des essais cliniques directs."
}
},
{
"@type": "Question",
"name": "Comment les A549 aident-elles à développer de nouveaux traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'évaluer l'efficacité et la toxicité des nouveaux composés thérapeutiques."
}
},
{
"@type": "Question",
"name": "Les cellules A549 peuvent-elles prédire la réponse au traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent fournir des indications sur la réponse aux traitements, mais ne sont pas définitives."
}
},
{
"@type": "Question",
"name": "Quels agents sont souvent testés sur les A549 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des agents chimiothérapeutiques comme le cisplatine et des inhibiteurs de tyrosine kinase."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent être étudiées avec les A549 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'étudier les complications liées aux traitements du cancer et aux métastases."
}
},
{
"@type": "Question",
"name": "Les A549 peuvent-elles simuler des complications pulmonaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont utilisées pour modéliser des complications comme la fibrose pulmonaire."
}
},
{
"@type": "Question",
"name": "Comment les A549 aident-elles à comprendre les complications du cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'étudier les interactions entre les cellules tumorales et le microenvironnement."
}
},
{
"@type": "Question",
"name": "Peut-on étudier la résistance aux traitements avec les A549 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent utilisées pour comprendre les mécanismes de résistance aux traitements."
}
},
{
"@type": "Question",
"name": "Les A549 sont-elles impliquées dans des complications métaboliques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être utilisées pour étudier les effets métaboliques des traitements anticancéreux."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont étudiés avec les A549 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme le tabagisme, l'exposition à des agents chimiques et la pollution."
}
},
{
"@type": "Question",
"name": "Les A549 aident-elles à identifier des facteurs génétiques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être utilisées pour étudier l'expression génique liée à des prédispositions au cancer."
}
},
{
"@type": "Question",
"name": "Comment les A549 sont-elles utilisées pour étudier l'environnement ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'évaluer l'impact des toxines environnementales sur les cellules pulmonaires."
}
},
{
"@type": "Question",
"name": "Peut-on étudier l'alimentation avec les A549 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, elles peuvent être utilisées pour explorer l'impact des nutriments sur le cancer."
}
},
{
"@type": "Question",
"name": "Les A549 sont-elles utiles pour étudier le stress oxydatif ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent utilisées pour examiner les effets du stress oxydatif sur les cellules."
}
}
]
}
]
}
Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China. Electronic address: taolm@ecust.edu.cn.
Will Rogers Institute Pulmonary Research Center and Hastings Center for Pulmonary Research, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Will Rogers Institute Pulmonary Research Center and Hastings Center for Pulmonary Research, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Department of Physiology and Neurosciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA.
Department of Biomedical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA, USA.
Sonny Astani Department of Civil and Environmental Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA, USA.
Will Rogers Institute Pulmonary Research Center and Hastings Center for Pulmonary Research, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Mork Family Department of Chemical Engineering and Materials Science, Viterbi School of Engineering, University of Southern California, Los Angeles, CA, USA.
Anti-EGFR targeted anti-cancer treatment is associated with various skin adverse events. Cetuximab is often associated with acneiform papules and skin disorders. Hypertrichosis cited in face pinnae an...
A 72-year-old female cancer patient presented deteriorating facial-pinnae hypertrichosis and eyelash prolongation post cetuximab infusion....
Consecutive cetuximab administration led to exaggerating hairy skin side effects, fully alleviated when the drug was discontinued....
To the best of our knowledge, this is the first reported case of an anti-EGFR-associated diffuse pinnae hypertrichosis presentation in a female patient in literature. This distinct entity can be easil...
This study explored the feasibility of cetuximab with chemoradiation in women with cervical carcinoma and evaluated fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F...
Eligible patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVB invasive carcinoma of the uterine cervix were treated on 1 of 3 dose levels (DL). DL1 consisted of neoa...
Of the 21 patients enrolled, 9, 3, and 9 were treated in DL1, DL2, and DL3, respectively. DL1 required dose reductions due to gastrointestinal toxicities. DL2 and 3 were tolerated with 1 dose-limiting...
Cetuximab with cisplatin 30 mg/m2 and radiotherapy was tolerated. 18F-FDG-PET/CT demonstrated early evidence of response to neoadjuvant cetuximab. With advances in precision oncology and the recent ap...
Cetuximab is a monoclonal antibody blocking the epidermal growth factor receptor (EGFR) in metastatic colorectal cancer (mCRC). However, cetuximab treatment has no clinical benefits in patients affect...
The prevalence of head and neck cancer (HNC) is increasing rapidly, and the prognosis is poor in the advance stage. For the patient suffering from advance stage HNC, the improvement in quality of life...
It was a single-centric prospective-observational study. Patients were divided into two cohorts based on the chemotherapy regimens they were prescribed. Patients in cohort 1 were prescribed with cetux...
Amongst 175 patients screened, 100 patients were enrolled which further distributed in cohorts 1 and 2 equally. The mean QALYs were 0.016 and 0.017 at the time of diagnosis, i.e., before initiation of...
The three-drug therapy consisting of cetuximab, cisplatin, and paclitaxel has shown significant improvement in patients' QALYs compared to two-drug regimens of cetuximab and cisplatin. Thus, if the th...
Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal cancer. Preclinical studies s...
In this phase 1-2, open-label, nonrandomized clinical trial, we assigned heavily pretreated patients with metastatic colorectal cancer with mutant KRAS G12C to receive adagrasib monotherapy (600 mg or...
As of June 16, 2022, a total of 44 patients had received adagrasib, and 32 had received combination therapy with adagrasib and cetuximab, with a median follow-up of 20.1 months and 17.5 months, respec...
Adagrasib had antitumor activity in heavily pretreated patients with metastatic colorectal cancer with mutant KRAS G12C, both as oral monotherapy and in combination with cetuximab. The median response...
The optimal maintenance strategy after induction chemotherapy with anti-epidermal growth factor receptor antibody for patients with RAS wild-type metastatic colorectal cancer (mCRC) remains to be deba...
To evaluate the efficacy and safety of maintenance therapy with single-agent cetuximab after FOLFIRI (leucovorin [folinic acid], fluorouracil, and irinotecan) plus cetuximab induction therapy....
The TIME (Treatment After Irinotecan-Based Frontline Therapy: Maintenance With Erbitux]) (PRODIGE 28 [Partenariat de Recherche en Oncologie Digestive]-UCGI 27 [UniCancer GastroIntestinal Group]) phase...
After first-line induction therapy with 8 cycles of FOLFIRI plus cetuximab, patients without disease progression were randomized (1:1) to biweekly maintenance with cetuximab or observation. On disease...
The primary end point was the 6-month progression-free rate from randomization. Analysis was performed on an intention-to-treat basis. An exploratory biomolecular analysis, using next-generation seque...
Of 214 patients enrolled (141 men [65.9%]; median age, 67 years [range, 23-85 years]), 139 were randomized to receive cetuximab (n = 67; 45 men [67.2%]; median age, 64 years [range, 34-85 years]) or t...
The randomized clinical trial did not meet its primary end point but suggests clinically meaningful PFS and OS benefits associated with cetuximab maintenance therapy. However, maintenance cetuximab or...
ClinicalTrials.gov Identifier: NCT02404935....
In this controlled, randomized, open-label phase II trial, 109 patients were randomly assigned, 107 of whom were included into the full analysis set (FAS). Patients were randomly assigned in a 2:1 rat...
Eighteen patients discontinued study treatment before the first tumor assessment, thus resulting in the ATP population of 89 patients. In these patients, ORR was 51% (30/59) in the cetuximab-based exp...
To our knowledge, FIRE-4.5 is the first prospective and randomized study investigating first-line treatment of...
EGFR inhibitors used in the treatment of metastatic wild-RAS colorectal cancer in combination with chemotherapy are associated with dermatologic side events that are low grade in most cases. We report...
Purpose of this analysis was to report data of the BEACON CRC trial used in the German Health Technology Assessment (HTA) and previously unpublished data focusing on the dual blockade (encorafenib + c...
Analyses included overall survival (OS) and time-to-event analyses of morbidity and safety....
A total of 220 patients received encorafenib + cetuximab and 221 patients ACT/control. Median OS was 9.3 (encorafenib + cetuximab) versus 5.9 months (ACT/control) (stratified hazard ratio (HR...
In the HTA, the German G-BA granted a "hint for a considerable additional benefit" of encorafenib + cetuximab compared to the ACT in BRAF...
Cetuximab, used to treat head and neck squamous cell carcinoma and metastatic colorectal cancer, can cause severe infusion reactions....
We report an 87-year-old East Asian woman with stage IV ileocecal signet ring cell carcinoma who experienced severe allergic reactions to cetuximab despite pre-treatment. A dose escalation method, inv...
This approach demonstrates a viable alternative for patients with hypersensitivity to cetuximab, warranting further research for personalized treatment optimization....